Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Evacuation and hCG surveillance
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Control haemorrhage without losing the pathway
Active heavy bleeding, shock, severe anaemia, respiratory compromise or thyrotoxic instability during suspected molar pregnancy makes evacuation an urgent resuscitative procedure rather than a routine day case.
Action: Call senior gynaecology, anaesthesia and transfusion support, use ABCDE care with large-bore access and crossmatched blood, correct immediately reversible hazards, and proceed to suction evacuation when the team judges it safe.
Purpose and principles
Plan safe evacuation of molar tissue, preserve diagnostic pathology and deliver reliable specialist hCG surveillance until resolution or escalation is formally confirmed.
Evacuation has three simultaneous goals: make the patient safe, empty abnormal intrauterine tissue and preserve enough material for definitive diagnosis. The operation should not be treated as an ordinary miscarriage procedure when imaging, hCG or systemic findings suggest a mole. Uterine vascularity, marked distension, anaemia, thyrotoxicosis and respiratory compromise can increase peri-operative risk. Senior gynaecology and anaesthesia therefore agree the location, personnel, blood preparation and monitoring before a stable patient enters theatre.
Suction evacuation is generally used for both complete and partial moles when the patient wishes to retain the uterus. Mechanical suction removes tissue while limiting repeated sharp curettage. Ultrasound guidance may help when anatomy or uterine size creates concern, according to operator and service practice. Avoid an oxytocic infusion before evacuation is complete because of concern about trophoblastic embolisation; immediate cervical preparation is safe, while prolonged prostaglandin preparation should be avoided. If excessive bleeding occurs after complete evacuation, follow the major-haemorrhage pathway and consider tranexamic acid 1 g IV with a single oxytocin 5 IU IV dose. Significant pre-completion haemorrhage needs a senior individual balance rather than an absolute prohibition.
Indications, selection and cautions
High operative risk
Major bleeding, severe anaemia, a very large uterus, respiratory symptoms or overt thyrotoxicosis signals need for enhanced theatre, anaesthetic and transfusion preparation.
Resolving hCG trajectory
Serial serum and urine hCG that steadily falls toward normal generally supports spontaneous clearance even when the decline takes several months.
Plateau or rise
Repeated values that flatten or increase may indicate active trophoblast and require specialist-centre assessment rather than another unplanned uterine procedure.
Delayed normalisation
A complete-mole hCG taking more than 56 days to normalise commonly enters a longer surveillance branch under the regional protocol.
Surveillance interference
A new pregnancy, inconsistent assay platform or rare analytical interference can confuse low-level hCG and should be resolved with the screening centre.
Red flags requiring action
Ongoing heavy bleeding, haemodynamic change or a rapidly enlarging uterus requires theatre and blood-product readiness rather than delay for every routine investigation.
Hypoxia, chest pain, breathlessness or haemoptysis before or after evacuation may indicate pulmonary oedema, embolic trophoblastic material, severe anaemia or metastatic disease.
Fever, agitation, arrhythmia or heart failure with severe biochemical thyrotoxicosis needs urgent medical and anaesthetic management around evacuation.
Assessment before treatment
01Pre-operative quantitative hCGFirst step
Why
Document baseline trophoblastic activity and help contextualise systemic and anaesthetic risk.
Interpretation and limitations
A high concentration supports extensive disease but does not alone predict bleeding or establish histological category; the centre needs the value and date.
02Full blood count and crossmatch
Why
Measure anaemia, platelet count and prepare compatible blood for anticipated uterine haemorrhage.
Interpretation and limitations
Use physiology and ongoing loss alongside haemoglobin, since acute bleeding can precede a large measured fall; thrombocytopenia changes procedural planning.
03Histology with ancillary tests
Why
Confirm hydatidiform mole and separate complete, partial and non-molar pregnancy tissue.
Interpretation and limitations
Morphology plus p57 and, when necessary, genotyping determines the correct surveillance label; macroscopic vesicles are not enough.
04Central serum and urine hCG
Why
Measure residual trophoblastic activity consistently through the national screening programme.
Interpretation and limitations
The trend, histological type and time since evacuation determine discharge or treatment assessment; one negative home test cannot close surveillance.
05
Treatment approach
01Before evacuationBuild a risk-matched theatre planFirst stepClinical assessment or ultrasound suggests complete or partial molar pregnancy.+
1Review observations, bleeding, uterine size, cardiopulmonary and thyroid symptoms and obtain full blood count, group, crossmatch, hCG and indicated organ tests.
2Involve senior gynaecology and anaesthesia, select a facility with appropriate transfusion and critical-care support and explain the procedure and follow-up implications.
3Confirm the patient's fertility preferences, consent for possible additional haemostatic procedures and a clear plan to label and send all tissue.
02During treatmentRemove tissue and manage bleedingDefinitiveThe patient reaches theatre for definitive uterine management.+
1Perform careful suction evacuation with experienced assistance and use ultrasound guidance when anatomy or service protocol makes it valuable.
Complications, monitoring and follow-up
Observe blood loss, pulse, blood pressure, oxygenation and recovery closely after evacuation, repeating haemoglobin or organ tests according to clinical change.
Check the final pathology rather than leaving an unexpected molar diagnosis in an unreviewed electronic result queue.
Maintain a dated surveillance record showing every requested and received serum or urine hCG until the centre sends formal discharge confirmation.
Ask about new pregnancy possibility, bleeding, chest symptoms and neurological symptoms at follow-up contacts and escalate deviations from the planned trajectory.
Support contraception, psychological recovery and future pregnancy planning, including early ultrasound and any centre-requested hCG after later pregnancy events.
Special situations
Falling slowly can still resolve
Persistent detectable hCG is not synonymous with neoplasia when values continue to decline; national centres interpret the pattern and treatment thresholds.
The assay is part of care
Central serum and urine measurements reduce platform variation and help resolve low-level false-positive or pregnancy-related results.
Tissue labelling changes outcomes
Telling pathology that mole is suspected prompts appropriate morphology and ancillary testing, preventing missed classification and absent surveillance.
The uterus is not the whole disease
Even definitive hysterectomy leaves a theoretical extrauterine trophoblastic burden, which is why hCG follow-up remains necessary.
Schedules evolve by centre
Use the current written instructions from the responsible screening programme instead of memorising an older universal six-month rule.
Common pitfalls
01
Undertaking a high-risk evacuation without adequate anaesthetic, blood-bank and senior gynaecology preparation.
02
Using medical induction routinely for a suspected complete mole without a specialist rationale.
03
Failing to send tissue or omitting the suspected-mole history from the pathology request.
04
Assuming hysterectomy removes the need for specialist hCG follow-up.
05
Calling a slowly falling hCG persistent cancer or calling one negative test complete resolution.
06
Repeating curettage for an abnormal trend before the trophoblastic centre reviews the case.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Follow-up after partial mole
A partial hydatidiform mole is confirmed after suction evacuation and the patient's hCG subsequently becomes normal. Which approach best reflects UK surveillance practice?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Medical management is not routine for a suspected complete mole. A partial mole may be diagnosed only after medical management of an apparent miscarriage, and occasionally fetal size or other circumstances make induction appropriate after specialist discussion. Whatever method is used, collect tissue for histopathology. State gestation, scan appearances and suspected trophoblastic disease on the request. Classification may need p57 immunohistochemistry, ploidy assessment or molecular genotyping, because surveillance differs and hydropic non-molar miscarriage is an important mimic.
Hysterectomy is an option for selected patients who have completed their family or have another uterine indication, but the decision must include operative morbidity and future fertility consequences. Ovaries are usually preserved unless a separate pathology exists; theca-lutein cysts commonly regress as hCG falls. Hysterectomy removes the principal site of disease but not occult circulating or extrauterine trophoblast, so the patient still enters the national hCG programme. It is not a biochemical follow-up shortcut. A non-sensitised RhD-negative patient should receive anti-D within 72 hours after surgical evacuation of either a complete or partial mole, including before 12 weeks; the separate early-abortion anti-D threshold does not apply to molar surgical evacuation.
After confirmed histology, the local team registers the patient with the regional trophoblastic screening centre and supplies the evacuation date, histological category, hCG values and clinical details. Central laboratories use consistent serum and urine assays and interpret serial change. Results are often requested every two weeks initially. A steadily falling level can remain abnormal for months without automatically indicating chemotherapy; a plateau, rise, heavy bleeding or other centre criterion triggers assessment for persistent neoplasia.
Duration cannot safely be reduced to one universal rule. Contemporary UK centre protocols complete partial-mole follow-up after hCG normalises and a further normal sample is obtained at the specified interval, commonly four weeks. For complete mole, timing depends on how quickly hCG becomes normal. Some current centres discharge after an early normal result is confirmed when normalisation occurs within 56 days, whereas delayed normalisation leads to monthly surveillance for a longer period, often six months from normalisation. Follow the named centre's written schedule because regional protocol and assay details matter.
Pregnancy should be deferred until the centre confirms discharge, since a new gestation creates hCG that cannot be distinguished from persistent trophoblast. Hormonal and barrier methods can start after evacuation. Do not normally insert a copper IUD or levonorgestrel IUS until hCG is normal or undetectable: UKMEC 2025 classifies intrauterine contraception as category 3 while hCG is decreasing and category 4 with persistently elevated hCG or malignant disease, so offer an acceptable bridging method. Avoid framing surveillance as indefinite infertility. Most patients later conceive normally, and recurrence risk remains low but higher than background. Explain what to do with a positive test during follow-up, arrange emotional support, and offer early ultrasound and any centre-requested post-pregnancy testing in the next pregnancy.
Key points
Suction evacuation is generally recommended for complete and partial molar pregnancy when fertility preservation is intended; select the setting according to bleeding, uterine size and systemic risk.
Prepare blood, experienced operators and anaesthetic support before starting. Avoid an oxytocic infusion until evacuation is complete because pre-completion use may promote trophoblastic embolisation; immediate cervical preparation is safe, but avoid prolonged prostaglandin preparation. If excessive bleeding follows complete evacuation, use the current major-haemorrhage pathway, including tranexamic acid 1 g IV and, when indicated, a single oxytocin 5 IU IV dose. Significant pre-completion haemorrhage requires a senior case-specific risk-benefit decision.
Avoid routine medical induction for a suspected complete mole; exceptional partial-mole circumstances require senior individual planning because tissue, fetal size and haemorrhage risk differ.
Send all evacuated material for histopathology with the clinical suspicion stated, and arrange expert review or genetic testing when classification is uncertain.
Hysterectomy can be considered when fertility is not desired and surgical risk is acceptable, but it does not remove the requirement for biochemical surveillance.
Register a confirmed mole with the appropriate UK screening centre, which supplies the assay and timetable; do not substitute ad hoc local hCG testing.
Current follow-up is type- and response-dependent: partial mole usually finishes after normal hCG plus a confirmatory sample, while delayed normalisation after complete mole requires a longer centre-directed period.
Advise avoiding pregnancy until discharge from surveillance, give written symptoms and contacts, and actively trace missed samples because reliable follow-up is part of treatment.
A plateau, rise or unexplained persistence in surveillance hCG must be reported to the trophoblastic centre and not managed with repeated local curettage by default.
A new pregnancy during follow-up makes hCG uninterpretable; contact the centre promptly for an individual plan rather than assuming recurrence or normal gestation.
Targeted thyroid and organ tests
Why
Identify peri-operative thyrotoxicosis, renal dysfunction and hepatic disturbance in clinically affected patients.
Interpretation and limitations
Correct major abnormalities and involve appropriate specialists; improving hCG should reduce gestational thyroid stimulation, while persistence suggests another diagnosis.
06Ultrasound for selected concerns
Why
Assess uterine contents, myometrial disease or haemorrhage when symptoms or hCG findings require anatomical review.
Interpretation and limitations
Residual intrauterine material does not by itself mandate re-evacuation; combine imaging with bleeding, hCG level and advice from the treatment centre.
2Monitor haemodynamics and blood loss continuously, avoiding an oxytocic infusion until evacuation is complete; use tranexamic acid and oxytocin after complete evacuation when excessive bleeding requires them, with significant pre-completion haemorrhage managed through a senior individual risk-benefit decision.
3EscalationEscalate uncontrolled bleeding through transfusion, tamponade, interventional radiology or surgery according to physiology and available senior expertise.
03Pathology confirmedTransfer into national follow-upHistopathology diagnoses a complete or partial hydatidiform mole.+
1Register promptly with the correct regional centre and transmit the evacuation date, histology, baseline hCG and any significant complication.
2Use the centre's sample kits and dates, assign responsibility for tracing each result and contact patients actively after missed specimens.
3Provide contraception, pregnancy-avoidance timing, written urgent symptoms, emotional support and a route for questions about results or future fertility.
04Concerning surveillanceLet trend trigger specialist assessmenthCG plateaus, rises or remains unexpectedly detectable, or heavy bleeding and systemic symptoms recur.+
1Contact the screening or treatment centre with the complete assay series and check pregnancy possibility, recent procedures and clinical stability.
2Arrange urgent local assessment for haemorrhage, respiratory or neurological symptoms while the centre directs staging and disease-specific decisions.
3Do not perform routine repeat curettage or start chemotherapy locally unless the specialist trophoblastic team has recommended that plan.